Mark G. Clemens – 30 December 2003

Ulrich Baumann, Heather A. Crosby, Pramila Ramani, Deirdre A. Kelly, Alastair J. Strain – 30 December 2003 – The stem cell factor (SCF)/c‐kit ligand/receptor system has been implicated in stem (oval) cell activation following liver injury in the rat. The aim of this study was to determine the role of the SCF/c‐kit system in pediatric human liver during acute and chronic liver injury. Tissue was obtained from hepatectomy specimens of patients undergoing liver transplantation for extrahepatic biliary atresia (EHBA) and fulminant hepatic failure (FHF).

Ronald L. Koretz – 30 December 2003

Shinji Tomida, Masato Abei, Takashi Yamaguchi, Yasushi Matsuzaki, Junichi Shoda, Naomi Tanaka, Toshiaki Osuga – 30 December 2003 – Whether ursodeoxycholic acid (UDCA) therapy alters the long‐term clinical course of gallstones (GS) without stone dissolution remains unknown. We aimed to clarify the relationship between long‐term UDCA therapy and risks of biliary pain or acute cholecystitis in GS patients. We also aimed to identify factors affecting the natural course, and to explore a simple patient selection criteria for UDCA therapy.

Michael Charlton, Philip Adjei, John Poterucha, Nizar Zein, Breanndan Moore, Terry Therneau, Ruud Krom, Russell Wiesner – 30 December 2003 – A novel DNA virus, TT‐virus (TTV), has been reported in patients with non–A‐G posttransfusion hepatitis in Japan. We sought to determine whether TTV infection occurs in North American blood donors and to further determine the prevalence of TTV infection in several groups of patients with liver disease, including patients with cryptogenic cirrhosis and idiopathic fulminant hepatic failure.

Anna Kordelia Kurz, Freimut Schliess, Dieter Häussinger – 30 December 2003 – The influence of cell hydration and taurine on the heat shock response was studied in primary rat hepatocytes. Heat‐induced accumulation of inducible heat shock protein 70 (HSP70) mRNA and protein was increased under hypo‐osmotic conditions. In contrast, hyper‐osmotic exposure blocked the HSP70 response during an 8‐hour recovery, and this was paralleled by a reduction of overall protein synthesis and an impairment of thermotolerance.

Philippe Lahaye, Khalid A. Tazi, Jean‐Pierre Rona, Olivier Dellis, Didier Lebrec, Richard Moreau – 30 December 2003 – Protein kinase C (PKC) modulates the activity and phosphorylation of the catalytic α‐subunit of sodium‐potassium‐adenosine triphosphatase (Na+/K+ ATPase) in normal arteries. Because PKC is altered in cirrhotic aortae, Na+/K+ ATPase may also be altered in these arteries. The aim of the present study was to investigate α‐subunit activity and phosphorylation in aortae from normal and cirrhotic rats, under baseline conditions and during exposure to PKC modulators.

Akos Heinemann, Christof H. Wachter, Peter Fickert, Michael Trauner, Rudolf E. Stauber – 30 December 2003 – We recently reported that vasopressin analogues correct the in vitro vascular hyporeactivity to adrenergic vasoconstrictors in portal hypertensive rats. The aim of the present study was to determine whether vasopressin reduces splanchnic blood flow in portal vein‐ligated (PVL) rats by restoring vasoconstrictor responsiveness in vivo. The ultrasonic transit time‐shift technique was used for blood flow measurements.

Jay S. Markowitz, Paul Martin, Andrew J. Conrad, James F. Markmann, Philip Seu, Hasan Yersiz, John A. Goss, Peter Schmidt, Anita Pakrasi, Lucy Artinian, Natalie G. Murray, David K. Imagawa, Curtis Holt, Leonard I. Goldstein, Risë Stribling, Ronald W. Busuttil – 30 December 2003 – Patients undergoing liver transplantation for hepatitis B–related liver disease are prone to recurrence. The mainstay of prophylaxis has been passive immunotherapy with hepatitis B immune globulin (HBIG).

Ginny L. Bumgardner, Jiashun Li, SACH APTE, MARIE HEININGER, WENDY L. FRANKEL 3 – 30 December 2003 – Adhesion molecules such as intercellular adhesion molecule‐1 (ICAM‐1) and vascular cell adhesion molecule‐1 (VCAM‐1) have been implicated in the pathogenesis of various inflammatory liver disease states, including viral and autoimmune hepatitis as well as liver allograft rejection.